PRA International, a life science contract research organization based in Raleigh, is forming a joint venture in China along with WuXi PharmaTech.
Financial terms of the agreement were not disclosed.
PRA offers clinical trial and research services in some 80 countries, including China.
WuXi offers services in China and the United States.
The joint venture that will focus on China will be an independent CRO, the companies said.
“PRA’s global experience and technical expertise and WuXi’s operational experience and knowledge in China are a perfect fit,” said Colin Shannon , PRA’s chief executive officer. “Our companies also share a culture dedicated to delivering excellent customer service, valuing employees and meeting the highest standards of quality. Clinical trials continue to expand in China, and this joint venture is another step we are taking to meet the needs of our clients by establishing a strong presence there. We look forward to working with WuXi to serve global life science companies conducting studies in China.”
